DDInter556 DDInter165
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved the use of baricitinib for the treatment of COVID-19 in May 2022.
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Hydromorphone
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Hydromorphone
Hydromorphone {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} (Compound) resembles {v} (Compound) Hydromorphone
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Morphine
Morphine {u} may lead to a major life threatening interaction when taken with {v} Hydromorphone
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Hydromorphone
Hydromorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opium
Opium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Encorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Hydromorphone
Hydromorphone {u} may lead to a major life threatening interaction when taken with {v} Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Nalbuphine
Nalbuphine {u} may lead to a major life threatening interaction when taken with {v} Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Baricitinib
Dihydrocodeine (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Hydromorphone (Compound) and Hydromorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Morphine (Compound) and Morphine may lead to a major life threatening interaction when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Hydromorphone (Compound) and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Hydromorphone (Compound) and Hydromorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib
Dihydrocodeine (Compound) resembles Nalbuphine (Compound) and Nalbuphine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib